
1. clin pharmacokinet. 2017 jan;56(1):25-40. doi: 10.1007/s40262-016-0424-1.

comparative clinical pharmacokinetics pharmacodynamics hiv-1 integrase
strand transfer inhibitors.

podany at(1), scarsi kk(1), fletcher cv(2).

author information: 
(1)antiviral pharmacology laboratory, college pharmacy, university nebraska
medical center, 986000 nebraska medical center, omaha, ne, 68198-6000, usa.
(2)antiviral pharmacology laboratory, college pharmacy, university nebraska
medical center, 986000 nebraska medical center, omaha, ne, 68198-6000, usa.
cfletcher@unmc.edu.

dolutegravir (dtg), elvitegravir (evg) raltegravir (ral) members the
latest class antiretrovirals (arvs) become available treat human 
immunodeficiency virus (hiv) infection: integrase strand transfer inhibitors
(instis). instis potent inhibitors hiv integrase enzyme, protein 
binding-adjusted concentration inhibiting viral replication 90/95 % [ic90/95] 
values low nanogram per millilitre range, retain antiviral
activity strains hiv acquired resistance classes of
arvs. instis unique pharmacokinetic/pharmacodynamic properties,
influencing role clinical use specific subsets patients. ral dtg
have minimal drug-drug interaction profiles, metabolism minimal
cytochrome p450 (cyp) involvement. conversely, evg metabolism occurs primarily
via cyp3a4 requires pharmacokinetic boosting achieve systemic exposures
amenable once-daily dosing. evg dtg added benefit availability
of fixed-dose combination tablets, allowing convenient simplified arv
regimens. ral insti listed preferred agent current 
us perinatal treatment guidelines. three instis recommended regimens 
treatment-naïve individuals us adult adolescent hiv treatment
guidelines. review summarizes compares pharmacokinetics and
pharmacodynamics instis, describes specific pharmacokinetic
considerations special patient conditions: hepatic impairment, renal
dysfunction, pregnancy co-infections.

doi: 10.1007/s40262-016-0424-1 
pmcid: pmc5164870
pmid: 27317415  [indexed medline]

